Business
Med Biogene Inc. appoints Erinn B. Broshko as its new Chief Executive Officer and a director
Med Biogene Inc. appoints Erinn B. Broshko as its new Chief Executive Officer and a director.
About this update from Many Bright Ideas Technologies Inc
[{"type":"text","content":"\n\n\n\n\nVANCOUVER, May 19 /CNW/ - Med BioGene Inc. (\"MBI\") (TSX Venture: MBI) is\npleased to announce the appointment of Erinn B. Broshko as Chief Executive\nOfficer and a director of MBI.\nPrior to joining MBI, Mr. Broshko was a corporate and securities lawyer\nwith the Vancouver law firm of Farris, Vaughan, Wills & Murphy LLP.\nMr. Broshko's legal practice was focussed primarily on biotechnology\ncompanies. Mr. Broshko holds a B.A. (hons) and M.A. from the University of\nSaskatchewan, an LL.B. from Dalhousie Law School and an M.B.A. from the\nUniversity of British Columbia.\n\"Erinn brings to MBI extensive business, legal and transactional\nexperience and we welcome his involvement as MBI continues through its\ndevelopment stage. He is a team player with a proven track record of\nleadership and is intimately familiar with our company's products and\nmanagement\", said Dr. Nathan Yoganathan, MBI's President and Chief Scientific\nOfficer.\nMr. Broshko said, \"I am enthusiastic about this opportunity because I\nbelieve that MBI can become a leader in molecular diagnostics. I intend to\nwork with the rest of the management team and the board of directors to focus\non delivering strong, consistent results for our shareholders.\"\n\nCorporate Matters\n\nMBI has granted to certain of its directors, officers, employees and\nconsultants five-year incentive stock options to purchase an aggregate of\n3,075,000 common shares at an exercise price of $0.40 per share.\n\nAbout Med BioGene\n\nMBI is a biotechnology company with advanced research expertise in gene\nexpression technology. MBI's mission is to become a market leader in the\nsupply of content for molecular-based diagnostic micro arrays. MBI intends to\nfulfill this mission by developing and marketing genetic content for molecular-\nbased human diagnostic tests. Molecular diagnostics, based on genetic\nexpression, is a developing technology field that has the potential to replace\ncertain of today's standard diagnostic tests. MBI intends to utilize its\nexpertise in gene expression, bioinformatics and micro arrays to develop the\ndiagnostic tests' genetic content. From the tens of thousands of genes in the\nhuman genome, MBI is attempting to identify those genes, known as \"bio\nmarkers,\" which mark the presence of various disease conditions.\nMBI's initial focus will be d...